The FDA was set to authorize their pills to treat coronavirus as soon as this week

22 December 2021, 02:59

Market Focus

US stock advanced on Tuesday amid risk-on market sentiment, rebounding from its biggest three-day slide since September as market demand for risk assets increased. Despite US Democrat Senator Joe Manchin’s rejection of the Biden administration’s $1.75T Build Back Better (BBB) social spending package yesterday, President Joe Biden said that he still has a chance to strike a deal with Manchin to get his roughly $2 trillion economic plan through Congress. Therefore, the possibly reviving talks on Biden’s economic agenda lend some support to stock markets. On top of that, Biden is also considering dropping travel restrictions against South Africa, where the new Omicron variant was first identified. Another news from Bloomberg reported that the US Food and Drug Administration was set to authorise their pills to treat coronavirus as soon as this week.

The benchmarks, S&P 500, Nasdaq 100 and the Dow Jones Industrial Average both rose on Tuesday as risk appetite flips positive in the American session as the prospect of President Joe Biden’s economic plans is also improving. S&P 500 was up 1.8%, while the Dow Jones Industrial Average also advanced with a 1.6% gain for the day. Nine out of eleven sectors stayed in positive territory as the energy and information technology sectors are the best performing among all groups, rising 2.89% and 2.60%, respectively. The Nasdaq 100 climbed the most with a 2.3% gain on Tuesday due to the surge in chipmaker Micron Technology Inc., and the MSCI World index rose 1.7%.

Main Pairs Movement

The US dollar edged lower on Tuesday, staying in negative territory amid an upbeat market mood despite the US 10-year yields ending 3.7% higher. The DXY index dropped to a daily low under 96.35 level during the European session, then rebounded back above 96.62 to offset most of its intraday’s losses. Investors now considered that vaccines helped tame the Omicron virus outbreak and the news that the US FDA is ready to authorize pills from Pfizer and Merck also favoured the US stock market and acted as a headwind for the safe-haven greenback.

GBP/USD advanced 0.47% on Tuesday as a broader recovery in risk appetite across markets favoured risk currency like British pounds. But traders will remain on notice for a new lockdown announcement that could come later in the week. The cable kept being pushed higher throughout the session, touching daily highs around the 1.326 area. Meanwhile, EUR/USD climbed to a daily top above 1.130 level but then retreated to surrender some of its intraday’s gains. The pair gained 0.09% for the day, as volumes are thinning ahead of the Christmas holidays.

Gold declined and touched a daily low under $1785 in the late American session, as the appetite for riskier assets dented demands in the precious metal. Meanwhile, WTI oil surged almost 3.0% for the day, as the risk-on market mood and positive news about the Omicron variant both acted as tailwind for the black gold.

Technical Analysis

XAUUSD (4- Hour Chart)

Gold has eased as the markets assess Omicron’s impact and the Fed’s plan on hiking rates. Fundamentally, gold is caught in a dilemma; although gold is considered a hedge against inflations, the Fed’s rate hikes at the same time increase the opportunity cost of holding non-yielding gold. As a result, expect to see a choppiness and a consolidating trend for gold. From the technical perspective, gold becomes bearish in the near- term, trading at 1787, as it falls below the 20 SMA, suggesting that gold has turned weak against the US dollar. Gold is expected to consolidate within the 1782 to 1800 range as the technical indicator RSI is neither in the overbought nor oversold territory, suggesting a directionless circumstance. On the upside, any subsequent move would face stiff and psychological resistance at 1800, followed by 1815. On the flip side, the 1765- 1770 region seems to protect the immediate downside, followed by 1753.

Resistance: 1800, 1815, 1829

Support: 1782, 1770, 1765, 1753

GBPUSD (4- Hour Chart)

GBPUSD gained traction in the early US trading session on Brexit headline, currently trading at 1.3252. However, the markets’ focus remains on the likelihood of stricter Covid restriction amid the spread of Omicron. From the technical perspective, bar the outbreak price action last Friday, GBPUSD has fallen back overall, turning into a consolidation phase in the range from 1.3163 to 1.3267. From the near-term outlook, the currency pair remains bearish as it continues to trade below the 20 and 50 SMAs. In the meantime, the bears are supported by a negative MACD, lending aids to the bears, although the RSI is currently directionless. On the upside, GBPUSD needs to climb above its resistance at 1.3267 in order to turn bullish in the near term.

Resistance: 1.3321, 1.3419, 1.3499

Support: 1.3163

AUDUSD (4- Hour Chart)

The RBA minutes seemed to deliver a few surprises for the Aussie, while the markets will focus on US data later this week. On the technical side, AUDUSD advances above the resistance at 0.7116, trading at 0.7142 at the time of writing. The four-hour outlook of the currency pair remains bullish as it continues to trade within the ascending channel. More importantly, both the MACD and RSI synchronously turn to the upside, meaning that buyers are taking control. AUDUSD is expected to head toward 0.717, the immediate hurdle; if the pair successfully breaches the level, then it will re-confirm the bullish trend. On the flip side, AUDUSD needs to hold steady above the ascending line to remain bullish.

Resistance: 0.717, 0.7227, 0.7277

Support: 0.6997